LitAlert ~~ GeneLit.com

    • Ideaya Biosciences, Broad Institute Partner on Synthetic Lethality-Based Cancer Drug Discovery.
    • [No author given]
    • GenomeWeb. Technology. Gene Silencing/Gene Editing. 2020 Oct 22.
    • PARP Inhibitors in Cancer Diagnosis and Therapy.
    • Chan CY, Tan KV, Cornelissen B.
    • Clin Cancer Res. 2020 Oct 20:clincanres.2766.2020. doi: 10.1158/1078-0432.CCR-20-2766. Epub ahead of print.
    • Review
    • Germline testing for homologous recombination repair genes - opportunities and challenges.
    • Hirsch S, Gieldon L, Sutter C, Dikow N, Schaaf CP.
    • Genes Chromosomes Cancer. 2020 Oct 20. doi: 10.1002/gcc.22900. Epub ahead of print.
    • Review
    • Repurposing denosumab in breast cancer beyond prevention of skeletal related events: could nonclinical data be translated into clinical practice?
    • Deligiorgi MV, Panayiotidis MI, Trafalis DT.
    • Expert Rev Clin Pharmacol. 2020 Oct 17. doi: 10.1080/17512433.2020.1839416. Epub ahead of print.
    • Review
    • Genetic and clinical landscape of breast cancers with germline BRCA1/2 variants.
    • Inagaki-Kawata Y, Yoshida K, Kawaguchi-Sakita N, Kawashima M, Nishimura T, Senda N, Shiozawa Y, Takeuchi Y, Inoue Y, Sato-Otsubo A, Fujii Y, Nannya Y, Suzuki E, Takada M, Tanaka H, Shiraishi Y, Chiba K, Kataoka Y, Torii M, Yoshibayashi H, Yamagami K, Okamura R, Moriguchi Y, Kato H, Tsuyuki S, Yamauchi A, Suwa H, Inamoto T, Miyano S, Ogawa S, Toi M.
    • Commun Biol. 2020 Oct 16;3(1):578. doi: 10.1038/s42003-020-01301-9.
    • Novel Agents for Metastatic Triple-Negative Breast Cancer: Finding the Positive in the Negative.
    • Vidula N, Ellisen LW, Bardia A.
    • J Natl Compr Canc Netw. 2020 Oct 15:1-9. doi: 10.6004/jnccn.2020.7600. Epub ahead of print.
    • The abundance of the long intergenic non-coding RNA 01087 differentiates between luminal and triple-negative breast cancers and predicts patient outcome.
    • De Palma FDE, Monaco VD, Pol JG, Kremer M, D'Argenio V, Stoll G, Montanaro D, Uszczynska-Ratajczak B, Klein CC, Vlasova A, Botti G, D'Aiuto M, Baldi A, Guigó R, Kroemer G, Maiuri MC, Salvatore F.
    • Pharmacol Res. 2020 Oct 14:105249. doi: 10.1016/j.phrs.2020.105249. Epub ahead of print.
    • Newly diagnosed ovarian cancer: Which first-line treatment?
    • Lorusso D, Ceni V, Daniele G, Salutari V, Pietragalla A, Muratore M, Nero C, Ciccarone F, Scambia G.
    • Cancer Treat Rev. 2020 Oct 9;91:102111. doi: 10.1016/j.ctrv.2020.102111. Epub ahead of print.
    • Review
    • The DNA damaging revolution.
    • Cetin B, Wabl CA, Gumusay O.
    • Crit Rev Oncol Hematol. 2020 Oct 3;156:103117. doi: 10.1016/j.critrevonc.2020.103117. Epub ahead of print.
    • Review
    • Patient Selection Biomarker Strategies for PARP Inhibitor Therapy.
    • Pilié PG, George A, Yap TA.
    • Ann Oncol. 2020 Sep 30. doi: 10.1016/j.annonc.2020.09.017. Epub ahead of print.
    • Editorial
    • Rapid Genetic Testing for BRCA1 and BRCA2 Mutations at the Time of Breast Cancer Diagnosis: An Observational Study.
    • Metcalfe KA, Eisen A, Poll A, Candib A, McCready D, Cil T, Wright F, Lerner-Ellis J, McCuaig J, Graham T, Sun P, Akbari M, Narod SA.
    • Ann Surg Oncol. 2020 Sep 28. doi: 10.1245/s10434-020-09160-8. Epub ahead of print.
    • Clinical Outcome-Related Mutational Signatures Identified by Integrative Genomic Analysis in Nasopharyngeal Carcinoma.
    • Dai W, Chung DL, Chow LK, Yu VZ, Lei LC, Leong MM, Chan CKC, Ko JMY, Lung ML.
    • Clin Cancer Res. 2020 Sep 28:clincanres.2854.2020. doi: 10.1158/1078-0432.CCR-20-2854. Epub ahead of print.
    • Olaparib treatment in older patients with ovarian cancer: need for 'real-world' data beyond clinical trials.
    • Liposits G, Wulff CN, Otland A, Fokdal LU.
    • Ecancermedicalscience. 2020 Sep 15;14:1104. doi: 10.3332/ecancer.2020.1104.
    • Molecular Biomarkers for Early Detection and Prevention of Ovarian Cancer-A Gateway for Good Prognosis: A Narrative Review.
    • Yadav G, Vashisht M, Yadav V, Shyam R.
    • Int J Prev Med. 2020 Sep 3;11:135. doi: 10.4103/ijpvm.IJPVM_75_19.